Home/ Stocks/ GHRS

GH Research PLC Ordinary Shares

GHRS XNAS

$18.61 +0.17 (+0.92%) ▲ 15-min delayed

Open

$18.56

High

$18.78

Low

$18.13

Volume

453.6K

Market Cap

$1.28B

About GH Research PLC Ordinary Shares

GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.

Employees: 73 Website →

Related Market News

No specific coverage for GHRS yet. Check out our latest market news or earnings calendar.

Get GHRS Alerts

Stay ahead with breaking news, price alerts, and expert analysis on GH Research PLC Ordinary Shares.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.